Point 2: Shareholder background Huali Industrial Group, the major shareholder, was changed to Fanghua Pharmaceutical Technology Co., Ltd., which is a company with 100% shares held by Huali Group. The registered capital of Fanghua Pharmaceutical Technology Company is 1 100 million. After the change of shareholders, Huali Group directly holds 65,438+000% equity of Fanghua Pharmaceutical Technology, while 95.285% equity of the original Huali Industrial Group is held by Huali Group, and the remaining 4.765,438+05% equity is held by Zhejiang Licheng Industrial Co., Ltd., which became a private company with Wang Li, the actual controller of Huali Group.
The third point: the operating performance of the repurchased joint-stock company in 20 10 has reached the trigger condition. In order to cooperate with the implementation of equity incentive, the company has proposed equity incentive fund and repurchased the company's shares from the secondary market as restricted shares for equity incentive. The repurchase period is from April 22, 20 1 year to July 20, 201year. By the end of June of 20 1 1, 10, the company had repurchased 365,000 shares, with an average transaction price of 19.54 yuan per share. This incentive includes five people, including Liu Qinqiang, the interim president, accounting for 35%, and Du Mingde, the vice president and secretary of the board of directors, accounting for 20%.
Point 4: In February 2009, Jianmin Dapeng, the exclusive producer of in vitro cultured bezoar, transferred 20 million assets (29.02% equity of Wuhan Changlian Biochemical Pharmaceutical Co., Ltd.) to the actual controller of Wuhan Biopharmaceutical at the price of 1 yuan. As a consideration, Wuhan Bio-Pharmaceutical canceled the pharmaceutical production license of in vitro cultured bezoar raw materials, making Jianmin Dapeng the exclusive producer of in vitro cultured bezoar. This asset replacement will not only increase the sales scale of Jianmin Dapeng's in vitro culture products, but also help stabilize the market price of the products. Jianmin Dapeng test-tube seedlings have formed an annual production capacity of 5000 kg.
Fifth, brand influence ranks among the top in China. The company is a national production base of Chinese patent medicines for children. Its predecessor was "Ye Kaitai Chinese Medicine Shop", and it is called the four oldest Chinese medicine shops in China together with "Beijing Tongrentang", "Hangzhou Hu Qing Yu Hall" and "Guangzhou Chen Liji". The annual production capacity is nearly one billion yuan, and it has the national famous "Jianmin" brand trademark and the national first-class protected varieties of traditional Chinese medicine.
Sixth point: Brand products Many companies have more than 80 brand-name product series, such as Longmu Zhuanggu Granule, Jianmin Yanhou Tablet and Jianpi Shengxue Granule. Among them, Long Mu Zhuanggu Granule is one of the first three first-class protected varieties of Chinese medicine in China, which fills the gap of treating rickets with Chinese medicine as the main body and is the first in China.
Point 7: During the 20 10 period of R&D work, the company completed the clinical research of new drugs, such as Kaiyuning tablets, Jiannaoning capsules and Xiaoer Niuhuang Jiere ointment, and the clinical research progressed smoothly. Five kinds of new drugs, Kaiyuning Tablets, won the special project of major new drug creation in the Twelfth Five-Year Plan, and six kinds of new Chinese medicine, Xiaoer Yiniuning Granules, won the new drug certificate. In 20 10 * * * *, 73 re-registration approvals were obtained.
Eighth point: On the premise that the performance indicators are up to standard and the incentive targets are qualified, the stock incentive company will purchase the company's A shares from the secondary market and award them to the incentive targets (50% for Liu Qinqiang, 20% for Du Mingde, 20% for Xiong Fuliang, and 0/0% for Sun Guizhi/KLOC). Restricted stock incentive plan is valid for seven years. The lock-up period is 12 months from the date of grant. During the lock-up period, the restricted shares granted to the incentive object according to this plan are locked and may not be transferred. The lock-up period is 24 months. During the unlocking period, if the unlocking conditions specified in this plan are met, the incentive object can apply for unlocking twice. The incentive plan consists of three independent annual plans, namely, 20 10-20 12, one for each award year, and 2009-201/the year before the award year is the assessment year. The audited net profit of main business in each assessment year must reach the basic trigger base, including 40 million yuan in 2009, 50 million yuan in 20 10 and 68 million yuan in 2010/year. In addition, from 2009 to 20 1 1 year, the audited industrial gross profit margin must reach 58.8%, 59% and 59.3%.
Point 9: Shareholder's Return Plan In August, the company made a shareholder's return plan for the next three years (20 12-20 14). In the next three years, under the premise of maintaining the continuity and stability of the profit distribution policy, the company will distribute dividends in cash, stock or a combination of cash and stock. The company will actively adopt the cash distribution method on the premise that the profits and cash flow can meet the normal operation and long-term development. If the company has no major investment plan or major cash expenditure, the accumulated profit distributed in cash in the next three years shall not be less than 30% of the annual distributable profit realized in the three years, and the specific dividend ratio in each year shall be proposed by the board of directors according to the company's annual profit status and future fund use plan.